<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369343</url>
  </required_header>
  <id_info>
    <org_study_id>3151A1-403</org_study_id>
    <nct_id>NCT00369343</nct_id>
  </id_info>
  <brief_title>Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women</brief_title>
  <official_title>A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine
      reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied
      in the development program for the treatment of major depressive disorder (MDD), for
      vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral
      diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will
      investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri-
      and postmenopausal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50. Change= 8 week adjusted mean HAM-D17 minus baseline adjusted mean HAM-D17</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the patient's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Remission</measure>
    <time_frame>8 weeks</time_frame>
    <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Response to Treatment</measure>
    <time_frame>8 weeks</time_frame>
    <description>A response is defined as ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= 8 week adjusted mean HAM-A score minus baseline adjusted mean score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months</measure>
    <time_frame>open label baseline and 6 months</time_frame>
    <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50. Change= Final Evaluation mean HAM-D17 minus baseline mean HAM-D17.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Improvement (CGI-I) Score</measure>
    <time_frame>6 months</time_frame>
    <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale the clinician rates how much the patient's illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving Remission</measure>
    <time_frame>6 months</time_frame>
    <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving a Response to Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>A responder is defined as a patient with ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression - 17-item (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months</measure>
    <time_frame>open label baseline to 6 months</time_frame>
    <description>The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= Final Evaluation mean HAM-A score minus baseline mean score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months</measure>
    <time_frame>open label baseline to 6 months</time_frame>
    <description>EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation-Emergent Signs and Symptoms (DESS) Total Score</measure>
    <time_frame>6 months</time_frame>
    <description>DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of &quot;new symptoms&quot; and &quot;old (but worse) symptoms&quot; (1) and 0 for &quot;old and unchanged symptom,&quot; &quot;absent,&quot; or &quot;old symptom but improved&quot; for a total possible range of 0 to 43. A higher score indicates more symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">381</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)</intervention_name>
    <description>DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, daily (QD), tablet form, treatment period up to 8 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peri- and postmenopausal women between the ages of 40 and 70 years, inclusive.

          -  A primary diagnosis of MDD, single or recurrent episode, without psychotic features
             using the modified International Neuropsychiatric Interview (MINI).

          -  Montgomery-Asberg Depression Rating Scale (MADRS) total score &gt; or = 22 at the
             screening and baseline visit.

        Exclusion Criteria:

          -  Use of oral estrogen-, progestin-, androgen-, or Selective Estrogen Receptor Modulator
             (SERM)-containing drug products 8 weeks before baseline.

          -  Current (within 12 months) psychoactive substance abuse or dependence (including
             alcohol), manic episode, post-traumatic stress disorder, obsessive-compulsive
             disorder, or a lifetime diagnosis of bipolar or psychotic disorder.

          -  A history or active presence of clinically important medical disease.

        Additional criteria apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72762</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New London</city>
        <state>Connecticut</state>
        <zip>06320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brown Deer</city>
        <state>Wisconsin</state>
        <zip>53223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2006</study_first_submitted>
  <study_first_submitted_qc>August 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <results_first_submitted>November 26, 2008</results_first_submitted>
  <results_first_submitted_qc>April 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2012</results_first_posted>
  <last_update_submitted>April 9, 2012</last_update_submitted>
  <last_update_submitted_qc>April 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>vasomotor symptoms</keyword>
  <keyword>menopause</keyword>
  <keyword>diabetic neuropathy</keyword>
  <keyword>fibromyalgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited in the United States from September 2006 to September 2007.</recruitment_details>
      <pre_assignment_details>Patients were screened over 4 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
          <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="155"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to return</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>inadvertently reported study completers</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of continuance tolerability</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not take study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
          <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="256"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="381"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.01" spread="6.50"/>
                    <measurement group_id="B2" value="52.56" spread="7.17"/>
                    <measurement group_id="B3" value="52.19" spread="6.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.</title>
        <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50. Change= 8 week adjusted mean HAM-D17 minus baseline adjusted mean HAM-D17</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Double-blind phase; modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, who took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Mixed model repeated measures (MMRM) modeling included all available observed data for each patient and no missing values were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
            <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.</title>
          <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50. Change= 8 week adjusted mean HAM-D17 minus baseline adjusted mean HAM-D17</description>
          <population>Double-blind phase; modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, who took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Mixed model repeated measures (MMRM) modeling included all available observed data for each patient and no missing values were imputed.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.64" spread="0.53"/>
                    <measurement group_id="O2" value="-8.33" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed Models Repeated Measures (MMRM) used baseline as a covariate and factors for center, week and treatment.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.53</ci_lower_limit>
            <ci_upper_limit>6.11</ci_upper_limit>
            <estimate_desc>DVS SR adjusted mean change minus placebo adjusted mean change.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score</title>
        <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the patient’s illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).</description>
        <time_frame>8 weeks</time_frame>
        <population>Double-blind phase, modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Missing data handled by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
            <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score</title>
          <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale, the clinician rates how much the patient’s illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse).</description>
          <population>Double-blind phase, modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Missing data handled by last observation carried forward (LOCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 (very much improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 (much improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.3"/>
                    <measurement group_id="O2" value="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 (minimally improved)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 (no change)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4"/>
                    <measurement group_id="O2" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 (minimally worse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 (much worse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 (very much worse)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>DVS SR compared to Placebo for CGI-I scores of either 1 (very much improved) or 2 (much improved).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Remission</title>
        <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
        <time_frame>8 weeks</time_frame>
        <population>Double-blind phase, modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Missing data handled by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
            <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Remission</title>
          <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
          <population>Double-blind phase, modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Missing data handled by last observation carried forward (LOCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>DVS SR compared with Placebo.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Logistic regression model with treatment and site as factors and baseline score as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.132</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>3.74</ci_upper_limit>
            <estimate_desc>Adjusted odds ratio of DVS SR to Placebo. Odds ratio adjusted for baseline, treatment and site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Response to Treatment</title>
        <description>A response is defined as ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
        <time_frame>8 weeks</time_frame>
        <population>Double-blind phase, modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Missing data handled by last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
            <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Response to Treatment</title>
          <description>A response is defined as ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
          <population>Double-blind phase, modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Missing data handled by last observation carried forward (LOCF).</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6"/>
                    <measurement group_id="O2" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>DVS SR compared with Placebo.</p_value_desc>
            <method>Chi-squared</method>
            <method_desc>Logistic regression model with treatment and site as factors and baseline score as a covariate.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.125</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.85</ci_lower_limit>
            <ci_upper_limit>5.27</ci_upper_limit>
            <estimate_desc>Adjusted odds ratio of DVS SR to Placebo. Odd ratio adjusted for baseline, treatment and site.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8</title>
        <description>The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= 8 week adjusted mean HAM-A score minus baseline adjusted mean score.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Double-blind phase; modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Mixed model repeated measures (MMRM) modeling included all available observed data for each patient and no missing values were imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
            <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8</title>
          <description>The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= 8 week adjusted mean HAM-A score minus baseline adjusted mean score.</description>
          <population>Double-blind phase; modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation. Mixed model repeated measures (MMRM) modeling included all available observed data for each patient and no missing values were imputed.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.62" spread="0.44"/>
                    <measurement group_id="O2" value="-5.89" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Mixed model Repeated Measures (MMRM) analysis adjusted mean score for baseline score, time and center.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.24</ci_lower_limit>
            <ci_upper_limit>4.23</ci_upper_limit>
            <estimate_desc>Adjusted mean difference = Placebo adjusted mean score minus DVS SR adjusted mean score.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8</title>
        <description>EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <population>Double-blind phase; modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Desvenlafaxine Succinate Sustained-Release (DVS SR)</title>
            <description>Double-blind Phase Days 1 to 7: 50 mg/day (one 50 mg tablet) Days 8 to 14: 100 mg/day (one 100 mg tables) Days 15 to 56: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Phase Placebo administered daily for 8 weeks Open-label Phase Days 57-63: 100 mg/day (one 100 mg tablet) Days 64-238: At the discretion of the investigator, patients assigned 100 mg/day (one 100 mg tablet) or 200 mg/day (two 100 mg tablets) Taper Phase Day 239 or at discontinuation: If patient taking 200 mg/day, then decreased to 100 mg/day for 7 days, and then decreased to 50 mg/day for 7 days. Patients taking 100 mg/day decreased to 50 mg/day for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8</title>
          <description>EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.</description>
          <population>Double-blind phase; modified intent to treat population, which included all randomized patients with a baseline HAM-D17 score ≥18, took ≥1 dose of study drug and had ≥1 post-baseline HAM-D17 evaluation.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.02"/>
                    <measurement group_id="O2" value="0.06" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Mixed Model Repeated Measures (MMRM) with treatment and site as factors and baseline as covariate.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>Adjusted mean difference = Placebo adjusted mean score minus DVS SR adjusted mean score.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months</title>
        <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50. Change= Final Evaluation mean HAM-D17 minus baseline mean HAM-D17.</description>
        <time_frame>open label baseline and 6 months</time_frame>
        <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR / DVS SR</title>
            <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo / DVS SR</title>
            <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months</title>
          <description>HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50. Change= Final Evaluation mean HAM-D17 minus baseline mean HAM-D17.</description>
          <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.52" spread="7.17"/>
                    <measurement group_id="O2" value="-12.45" spread="6.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Improvement (CGI-I) Score</title>
        <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale the clinician rates how much the patient’s illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse)</description>
        <time_frame>6 months</time_frame>
        <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR / DVS SR</title>
            <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo / DVS SR</title>
            <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Improvement (CGI-I) Score</title>
          <description>CGI-I is a global rating scale that measures disease improvement. Using a 7-point scale the clinician rates how much the patient’s illness has improved or worsened relative to the baseline status (1= very much improved; 7= very much worse)</description>
          <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="1.00"/>
                    <measurement group_id="O2" value="1.56" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving Remission</title>
        <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50.</description>
        <time_frame>6 months</time_frame>
        <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR / DVS SR</title>
            <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo / DVS SR</title>
            <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving Remission</title>
          <description>Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total s core of 50.</description>
          <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving a Response to Treatment</title>
        <description>A responder is defined as a patient with ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression - 17-item (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
        <time_frame>6 months</time_frame>
        <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR / DVS SR</title>
            <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo / DVS SR</title>
            <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving a Response to Treatment</title>
          <description>A responder is defined as a patient with ≥ 50% decrease from baseline on Hamilton Psychiatric Rating Scale for Depression - 17-item (HAM-D17) score. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50.</description>
          <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
          <units>percentage of patients responding</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5"/>
                    <measurement group_id="O2" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months</title>
        <description>The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= Final Evaluation mean HAM-A score minus baseline mean score.</description>
        <time_frame>open label baseline to 6 months</time_frame>
        <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR / DVS SR</title>
            <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo / DVS SR</title>
            <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months</title>
          <description>The HAM-A is a standardized, clinician-administered rating scale that assesses 14 items characteristically associated with major anxiety disorders. Items are scaled 0 - 4 (0=none and 4=very severe), with a maximum total score of 56. Change= Final Evaluation mean HAM-A score minus baseline mean score.</description>
          <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.95" spread="6.90"/>
                    <measurement group_id="O2" value="-10.38" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months</title>
        <description>EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.</description>
        <time_frame>open label baseline to 6 months</time_frame>
        <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>DVS SR / DVS SR</title>
            <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
          </group>
          <group group_id="O2">
            <title>Placebo / DVS SR</title>
            <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months</title>
          <description>EQ-5D is a standardized, subject-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health). Change=8 week score minus baseline score.</description>
          <population>Open-label phase safety population: All patients who completed the double-blind phase, elected to continue treatment in the open-label phase, and received at least 1 dose of study drug in the open-label phase. One patient did not have a baseline and at least 1 on therapy assessment.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.26"/>
                    <measurement group_id="O2" value="0.22" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation-Emergent Signs and Symptoms (DESS) Total Score</title>
        <description>DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of “new symptoms” and “old (but worse) symptoms” (1) and 0 for “old and unchanged symptom,” “absent,” or “old symptom but improved” for a total possible range of 0 to 43. A higher score indicates more symptoms.</description>
        <time_frame>6 months</time_frame>
        <population>Open-label (OL) safety population: Patients completed double-blind and continued in OL with ≥1 dose study drug. Excluded patients lost to follow-up and discontinued with &lt;4 wks therapy. Patients analyzed varied by time (0mg, 100mg, 200mg): Early Termination (n=9,98,207); Taper week 1 (n=4,76,193); Taper week 2 (n=5,75,195); Post-taper (n=5,71,192)</population>
        <group_list>
          <group group_id="O1">
            <title>0 mg</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>100 mg</title>
            <description>DVS SR 100mg dosage was reduced to DVS SR 50mg for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>200 mg</title>
            <description>DVS SR 200mg dosage was reduced to DVS SR 100mg for 7 days and then further reduced to DVS SR 50mg from days 8 to 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Discontinuation-Emergent Signs and Symptoms (DESS) Total Score</title>
          <description>DESS: a clinician-administered 43-item assessment that evaluates discontinuation-emergent symptoms resulting from the withdrawal from test article. The DESS total score is the sum of the number of “new symptoms” and “old (but worse) symptoms” (1) and 0 for “old and unchanged symptom,” “absent,” or “old symptom but improved” for a total possible range of 0 to 43. A higher score indicates more symptoms.</description>
          <population>Open-label (OL) safety population: Patients completed double-blind and continued in OL with ≥1 dose study drug. Excluded patients lost to follow-up and discontinued with &lt;4 wks therapy. Patients analyzed varied by time (0mg, 100mg, 200mg): Early Termination (n=9,98,207); Taper week 1 (n=4,76,193); Taper week 2 (n=5,75,195); Post-taper (n=5,71,192)</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of 8 week DB / OL phase or early termination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="5.05"/>
                    <measurement group_id="O2" value="2.07" spread="4.03"/>
                    <measurement group_id="O3" value="1.27" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="2.16"/>
                    <measurement group_id="O2" value="3.32" spread="4.35"/>
                    <measurement group_id="O3" value="2.47" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taper week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="3.13"/>
                    <measurement group_id="O2" value="5.29" spread="5.96"/>
                    <measurement group_id="O3" value="3.76" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-taper</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.89"/>
                    <measurement group_id="O2" value="1.41" spread="2.18"/>
                    <measurement group_id="O3" value="2.46" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>100mg vs. Placebo (0mg) post taper</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.553</p_value>
            <p_value_desc>t-test adjusted by multiple comparison</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>200mg vs. Placebo (0mg) post taper</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>t-test adjusted by multiple comparison</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Double-blind DVS SR</title>
          <description>Days 1 to 7:
Patients will be instructed to take 1-50mg tablet per day
Days 8 to 14:
Patients will be instructed to take 1-100mg tablet per day
Days 15 to 56:
At the discretion of the investigator, patients may be assigned to 100mg or 200mg tablets per day</description>
        </group>
        <group group_id="E2">
          <title>Double-blind Placebo</title>
          <description>Placebo administered daily for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Open-label DVS SR/ DVS SR</title>
          <description>Patients were in the DVS SR arm during both the double-blind and open-label phase.</description>
        </group>
        <group group_id="E4">
          <title>Open-label Placebo/DVS SR</title>
          <description>Patients were in the Placebo arm during the double-blind phase and the DVS SR arm during the open-label phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="2"/>
                <counts group_id="E3" subjects_affected="12"/>
                <counts group_id="E4" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Medication error</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Psychotic depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine fibroids enlarged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Endometrial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Skin melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="217"/>
                <counts group_id="E2" subjects_affected="94"/>
                <counts group_id="E3" subjects_affected="198"/>
                <counts group_id="E4" subjects_affected="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Accidental injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Flu syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Vasodilatation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="256"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="208"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PIs agreed to allow the sponsor 60 days to review and require changes to presentations or publications but only to protect confidential information and intellectual property, and for the sponsor to file a patent application, as applicable. The PIs also agreed for data to be presented first as a joint, multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>U. S. Contact Center</name_or_title>
      <organization>Wyeth</organization>
      <email>clintrialresults@wyeth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

